ArticleInflammopharmacology2026
CircRNA HIPK2-mediated metabolic reprogramming restores mitochondrial homeostasis in chondrocytes through the miR-206/Sirt3 signaling axis attenuating osteoarthritis-induced nociception.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a degenerative joint disorder marked by chondrocyte metabolic dysfunction and mitochondrial impairment. This study elucidates the role of circHIPK2, a circular RNA downregulated in OA chondrocytes, in regulating glucose metabolism and mitochondrial homeostasis through the miR-206-SIRT3 axis. Clinical samples revealed significant circHIPK2 reduction and miR-206 upregulation in OA chondrocytes, correlating inversely with SIRT3 expression. In vitro LPS-induced injury models demonstrated that circHIPK2 overexpression mitigated chondrocyte apoptosis and metabolic stress, while miR-206 inhibition reversed LPS-driven glycolytic activation and mitochondrial dysfunction. Mechanistically, circHIPK2 directly bound miR-206 via Ago2-dependent interactions, as confirmed by RNA pull-down and luciferase assays, thereby alleviating miR-206-mediated suppression of SIRT3, a key mitochondrial deacetylase. Rescue experiments in chondrocytes showed that SIRT3 restoration rescued miR-206-induced metabolic defects, including impaired oxidative phosphorylation and ATP depletion. In vivo, intra-articular delivery of circHIPK2 in a monosodium iodoacetate (MIA)-induced OA rat model attenuated mechanical allodynia, cartilage degradation, and aberrant miR-206/SIRT3 expression, while improving weight-bearing symmetry; furthermore, similar therapeutic benefits-including pain relief, functional recovery, and cartilage protection-were confirmed in a chronic, post-traumatic destabilization of the medial meniscus (DMM) model, with efficacy demonstrated against appropriate AAV control groups. These findings identify the circHIPK2-miR-206-SIRT3 axis as a critical regulator of chondrocyte bioenergetics and OA progression, offering novel therapeutic targets for modulating non-coding RNA networks in joint degeneration.
Indexed as
Identifiers
41555117What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.